Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental Parkinsonism

Gene Therapy

Volumn 5, Issue 12, 1998, Pages 1650-1655

  Segovia, J ^a   Vergara, P ^b   Brenner, M ^b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b NONE

Author keywords

6 Hydroxydopamine (6 OHDA); Glial fibrillary acidic protein; Intracerebral gene transfer; Parkinson's disease; Promoter; Tyrosine hydroxylase

Indexed keywords

CATECHOLAMINE; COMPLEMENTARY DNA; DNA; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; LEVODOPA; LIPOSOME; NEUROTRANSMITTER; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BEHAVIOR; BRAIN INJURY; CATECHOLAMINE SYNTHESIS; CELL TRANSPLANTATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; GENE EXPRESSION; GENE TRANSFER; IMMUNOFLUORESCENCE; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PUTAMEN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE;

ANIMALIA;

EID: 0032416077     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300776     Document Type: Article

References (17)

1. Kopin, IJ. The pharmacology of Parkinson's disease therapy: an update. Annu Rev Pharmacol Toxicol 1993; 32: 467-495.
2. Ungerstedt U, Arbuthnott G. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-493.
3. Björklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177: 555-560.
4. Perlow MJ et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979; 204: 643-647.
5. Herman J-P, Abrous ND. Dopaminergic neural grafts after fifteen years: results and perspectives. Prog Neurobiol 1994; 44: 1-35.
6. Snyder EY, Senut M-C. The use of nonneuronal cells for gene delivery. Neurobiol Dis 1997; 4: 69-102.
7. Fisher LJ, Gage FH. Novel therapeutic directions for Parkinson's disease. Mol Med Today 1995; 1: 181-187.
8. Horellou P, Mallet J. Gene therapy for Parkinson's disease. Mol Neurobiol 1997; 15: 241-256.
9. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-1403.
10. Horellou P et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 1994; 6: 49-53.
11. Kaplitt MG et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
12. Cao L et al. Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Hum Gene Ther 1995; 6: 1497-1501.
13. Madrazo I et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. New Engl J Med 1987; 316: 831-834.
14. Goetz CG et al. Multicenter study of autologous adrenal medulla transplantation to the corpus striatum in patients with advanced Parkinson's disease. New Engl J Med 1989; 320: 337-341.
15. Lindvall O et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574-577.
16. Kordower JH et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. New Engl J Med 1995; 332: 1118-1124.
17. Muller DPR. Neurological disease. Adv Pharmacol 1997; 38: 557-580.